Skip to main content
OpenTrials
Completed

NCT Number: NCT01425411

Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular hypertrophy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiomegaly Cardiovascular Diseases Heart Diseases Hypertrophy Hypertrophy, Left Ventricular Left Ventricular Hypertrophy Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Mustafa Kemal University School of Medicine, Department of Cardiology

Antioch, 31100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hypertension with left ventricular hypertrophy

Exclusion criteria

  • clinical or laboratory evidence of secondary hypertension
  • heart failure
  • ischemic heart disease
  • valvular heart disease
  • arrhythmias
  • peripheral vascular disease
  • chronic obstructive pulmonary disease
  • neurologic disorders
  • diabetes mellitus
  • renal dysfunction
  • notable systemic disease

Treatment and study plan

valsartan

Drug

80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months

Other names: Diovan 80 mg, Diovan 160 mg, Co-diovan 160/12,5 mg

Primary outcomes

  1. change from baseline in midwall fractional shortening (mFS) and tissue Doppler systolic wave (Sm) measured by echocardiography at six months

    Time frame: six months

Secondary outcomes

  1. change from baseline in systolic and diastolic blood pressure at six months

    Time frame: six months

  2. change from baseline in left ventricular mass index measured by echocardiography at six months

    Time frame: six months

Sponsors and collaborators

Lead sponsor

Mustafa Kemal University

Other

Collaborators

  • Novartis Pharmaceuticals

Registry information

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Aug 30, 2011
Registry last updated
Aug 30, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.